Target intelligence / Profile preview

RNA, U6 small nuclear 829, pseudogene (RNU6-829P)

Target
RNU6-829P
Molecular classification
Other: Pseudogene, Noncoding RNA pseudogene
01

Overview

RNA, U6 small nuclear 829, pseudogene (RNU6-829P) is a noncoding pseudogene found in the human genome, located at cytogenetic region 9q22.31[7]. It is classified as a pseudogene of the U6 small nuclear RNA gene family, which are short noncoding RNAs essential for spliceosomal activity in mRNA processing. Unlike functional U6 snRNAs, RNU6-829P does not produce a functional RNA product and is not incorporated into the spliceosome[2][5]. Pseudogenes such as RNU6-829P are molecular records of past genomic events, typically resulting from retrotransposition or gene duplication followed by mutational inactivation[2]. While some pseudogenes can have regulatory roles, there is no evidence that RNU6-829P has any such function or relevance to disease, drug response, or biomarker status; it remains a nonfunctional genomic element in current scientific knowledge[5][4]. If further structured information is required, refer to genetic databases using the provided identifiers or consult recent pseudogene functional studies for potential emerging roles not yet established for RNU6-829P specifically.

Other names
RNU6-829PHGNC: 47792 (gene symbol database)NCBI Gene: 106479933Ensembl: ENSG00000200570Previous identifiers (e.g., GC09P096139)
02

Mechanism of action

None established for this pseudogene. There is no evidence that drugs target or act through RNU6-829P.

03

Biological functions

No established direct biological function. U6 snRNA pseudogenes are largely nonfunctional genomic elements. Unlike functional U6 snRNA, pseudogenes do not participate in the spliceosome or mRNA splicing[2].In rare cases, some pseudogenes can have regulatory functions at the RNA level, for instance as regulatory noncoding RNAs, but this has not been documented specifically for RNU6-829P[4].
04

Disease associations

No established direct disease association for RNU6-829P[5][7].Some pseudogenes as a class can participate indirectly in disease by acting as competitive endogenous RNAs or regulatory RNAs, but not all do, and there is no evidence that RNU6-829P plays such a role[4].
05

Safety considerations

No toxicity, safety concerns, or therapeutic challenges associated with this pseudogene[5].
06

Interacting drugs

None known[5]. There are no documented drugs interacting with this pseudogene.
07

Biomarkers

None established for RNU6-829P[5].

Beyond the preview

Go deeper on RNA, U6 small nuclear 829, pseudogene (RNU6-829P).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA, U6 small nuclear 829, pseudogene (RNU6-829P).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call